FRANKREICH

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Retrieved on: 
Mercredi, avril 10, 2024
Wealth, Aix-en-Provence, TP ICAP, TP, Ticker, Medtech, Security (finance)

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
  • Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.
  • Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024.
  • In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.

RALLYE S.A.: Restructuring of Casino Liquidation of holding companies

Retrieved on: 
Mercredi, avril 10, 2024

Rallye, Foncière Euris, Finatis and Euris acknowledge the effective completion of Casino's financial restructuring on 27 March 2024.

Key Points: 
  • Rallye, Foncière Euris, Finatis and Euris acknowledge the effective completion of Casino's financial restructuring on 27 March 2024.
  • Following this restructuring, Rallye holds approximately 0.1% of Casino's share capital and has therefore lost control.
  • As indicated in the press release dated 27 February 2024, Rallye, Foncière Euris, Finatis and Euris have therefore requested the termination of their safeguard plan and the opening of compulsory liquidation proceedings.
  • Rallye, Foncière Euris and Finatis will request the suspension of the listing of their shares and other listed instruments issued by them, with effect from the opening of the compulsory liquidation proceedings.

BILENDI: Bilendi now offers BARI, the AI-powered research assistant, for quantitative projects

Retrieved on: 
Mercredi, avril 10, 2024
Messenger, Professional, LLM, Data, Semantics, Qualitative research, Research, WhatsApp, Risk management

Now, BARI is also available to assist with quantitative projects.

Key Points: 
  • Now, BARI is also available to assist with quantitative projects.
  • In theory, open-ended questions in quantitative research greatly enhance the richness and depth of data.
  • In practice, however, participants in quantitative research tend to provide minimalistic answers that lack the depth found in responses from qualitative studies.
  • Marc Bidou, CEO and founder of Bilendi, states:
    “Clients often ask when our AI-powered research assistant will be available for quantitative projects.

Samba Digital, Inc: Samba Digital announces the creation of a new “Data Analytics” department intended to maximize digital marketing performance for its clients

Retrieved on: 
Mercredi, avril 10, 2024
ROI, Data analysis, ROO, Dugout, Sport, Marketing, Sales

Lisbon (Portugal) – April 10, 2024 - 6 p.m.: Samba Digital (ISIN PTDGL0AM0003, Mnemonic MLSMB), pioneer in digital marketing for rights holders, announces the launch of its new Data Analytics department, to respond as accurately as possible to the constant evolution of the market and the needs of its customers.

Key Points: 
  • Lisbon (Portugal) – April 10, 2024 - 6 p.m.: Samba Digital (ISIN PTDGL0AM0003, Mnemonic MLSMB), pioneer in digital marketing for rights holders, announces the launch of its new Data Analytics department, to respond as accurately as possible to the constant evolution of the market and the needs of its customers.
  • Investing not only in talent, Samba Digital is also developing and integrating cutting-edge tools for performance analysis and decision-making.
  • In collaboration with the best technologies on the market, the solutions developed by Samba Digital are based on social and media performance measurement tools, encompassing behavioral data and market research.
  • This new offering, focused on enhanced use of technology should contribute to Samba Digital's revenue from 2024 and support its growth trajectory in the medium term.

Guerbet: Change in Guerbet’s Board of Directors.

Retrieved on: 
Mercredi, avril 10, 2024
Financial management, Supervisory board, Trust, Central nervous system, Patient, GBT, Sanofi, Hospital, Mass meeting, Audit committee, MBA, OTC, BPI, Management

Guerbet: Change in Guerbet’s Board of Directors.

Key Points: 
  • Guerbet: Change in Guerbet’s Board of Directors.
  • Hugues Lecat’s appointment as a director will be submitted for approval at the next Shareholders’ Meeting.
  • The management experience acquired by Hugues in large companies in the pharmaceutical sector will help guide the Group in achieving further success.
  • Hugues was also a member of the Board of Directors of NOVASEP on behalf of BPI between 2012 and 2017.

2CRSi announces the large success of its €12 million fundraising

Retrieved on: 
Mercredi, avril 10, 2024
Private, Growth, Trust, History, Artificial intelligence, Combined, HAW, Euronext, NVIDIA, Security (finance)

Fund raising of approximately €12 million through the issue of 3,260,870 new shares for €10.9 million to qualified investors and for €1.1 million to retail investors via the PrimaryBid platform.

Key Points: 
  • Fund raising of approximately €12 million through the issue of 3,260,870 new shares for €10.9 million to qualified investors and for €1.1 million to retail investors via the PrimaryBid platform.
  • Strasbourg (France), 14 March 2024 - 2CRSi (ISIN: FR0013341781) (the “Company”), the leader in the design and manufacture of energy-efficient high performance IT servers, announces the large success of its fundraising for a total amount of €12 million (the “Global Offering”) from qualified investors, via accelerated bookbuilding, for an amount of €10.9 million (the “Private Placement”), and from retail investors, via the PrimaryBid platform, for an amount of €1.1 million (the “PrimaryBid Offering”).
  • Alain Wilmouth, Founder, Chairman and CEO of 2CRSi, noted: “We express our gratitude to our long-standing shareholders for their trust, and to all other investors, whether professional or individual, for their participation in this fundraising effort.
  • This market, in which 2CRSi enjoys international recognition, is driven by an explosion in global demand high-performance server technology solutions and hosted computing power and represents a major growth driver for 2CRSi.

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
Mercredi, avril 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Kaufman & Broad SA: AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT

Retrieved on: 
Mercredi, avril 10, 2024
AMF, KB Home, Audit

Kaufman & Broad, a French national real estate developer, filled its 2023 Universal Registration Document, with the Autorité des Marchés Financiers (AMF) on March 28, 2024.

Key Points: 
  • Kaufman & Broad, a French national real estate developer, filled its 2023 Universal Registration Document, with the Autorité des Marchés Financiers (AMF) on March 28, 2024.
  • The Universal Registration Document is available free of charge and upon request at the office of Kaufman & Broad SA (17, quai Président Paul Doumer 92400 Courbevoie France) and on the websites of the Company ( www.kaufmanbroad.fr ) and the AMF ( www.amf-france.org ).
  • The Universal Registration Document includes in particular:
    The Board of Directors management report of the Company;
    The Board of Directors report on the Company’s Corporate Governance;
    The fees of the statutory auditors.

Aéma Groupe: FY 2023 Results

Retrieved on: 
Mercredi, avril 10, 2024
Health, FIR, Mining, Principle, Growth, Face, UMG, MMJ, Environment, Partnership, Pension, Climate, Acquisition, Insurance, Carbon, Biodiversity, Investment, Ecosystem, Socially responsible investing, PRI, Om, Weather

Pascal Michard, Aéma Groupe Chairman of the Board of Directors, said:

Key Points: 
  • Pascal Michard, Aéma Groupe Chairman of the Board of Directors, said:
    "In 2023 we completed the group's structure, and confirmed our mutualist mission at the service of everyone.
  • Since 2021, Aéma Groupe has invested more than 6 billion euros in green, social and sustainable bonds, including more than 1.3 billion euros in 2023.
  • Aéma Groupe's first strategic plan, Cap 2023 "Building to conquer", established a new leading mutualist player in the French insurance market.
  • Encouraged by this successful growth, the group has announced a new strategic plan: "Aéma 2026: À vos marques!” ["Aéma 2026 : on your marks!” - the French word “Marque” means “Brand”].

EQS-News: Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline

Retrieved on: 
Mercredi, avril 10, 2024
Translocase, Partner, 5T4, Growth, Science, Patient, Doctor of Philosophy, Spacecraft, Andera-ye Olya, AACR, ADC, Annual general meeting, Fine chemical

Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.

Key Points: 
  • Tubulis is developing a pipeline of uniquely matched antibody drug conjugates (ADCs) with an indication-tailored targeting molecule and payload combination to develop novel ADCs with superior properties.
  • The proceeds of the Series B2 will primarily support progress in Tubulis’ pipeline of next-generation ADCs toward clinical evaluation and help achieve clinical proof-of-concept for lead candidates, TUB-040 and TUB-030.
  • The company expects to start its first Phase 1/2a clinical trial, including dose escalation and dose optimization cohorts in 2024.
  • “This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space.